Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:age |
adults
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:comparator |
platinum-based chemotherapy
|
| gptkbp:conditionStudied |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:endPoint |
overall survival
progression-free survival |
| gptkbp:enrollment |
305
|
| gptkbp:fullName |
gptkb:KEYNOTE-024:_Pembrolizumab_versus_Chemotherapy_for_PD-L1–Positive_Non–Small-Cell_Lung_Cancer
|
| https://www.w3.org/2000/01/rdf-schema#label |
KEYNOTE-024
|
| gptkbp:includes |
PD-L1 expression on at least 50% of tumor cells
|
| gptkbp:intervention |
gptkb:pembrolizumab
|
| gptkbp:location |
multinational
|
| gptkbp:number |
gptkb:NCT02142738
|
| gptkbp:principalInvestigator |
gptkb:Martin_Reck
|
| gptkbp:publishedIn |
gptkb:N_Engl_J_Med._2016;375(19):1823-1833
|
| gptkbp:result |
pembrolizumab improved progression-free and overall survival compared to chemotherapy
|
| gptkbp:sponsor |
gptkb:Merck_&_Co.
|
| gptkbp:startDate |
2014
|
| gptkbp:status |
completed
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|